These include the demonstration of increased histone acetylation in patients' PBMC in the early trials [14], [29], [30] and the more recent confirmation of changes in tumor expression of acetylated histone and non-histone proteins [10], [14], [31], [32], the HDAC2 enzyme [31] and HR23B protein [33], [34], the latter been proposed as predictive biomarker [35], and of tumor proliferation index [36]. Here, HDAC2 is linked to neoplasm.